Endo buys Par Pharma for $8B to expand generics

May 18, 2015 12:11 PM

66 0

Endo International (ENDP) said Monday it has agreed to pay $8.05 billion to private equity firm TPG to buy Par Pharmaceutical Holdings, a deal aimed at expanding its growing generics business.

The stock-and-cash deal, approved by the boards of both companies, will create one of "the top five" generics manufacturers in terms of U.S. sales, Endo said.

Also read: Britain Unlikely to Review Comcast’s $30 Billion Sky Deal

Read more

To category page